Ubong Udofia
Psychiatric/Mental Health · Marlton, NJNPI 1760745889
Payments from drug & device makers
Across 1,832 payments — averaging $221.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$248K
- Teva Pharmaceuticals USA, Inc.$65K
- AbbVie$50K
- Axsome Therapeutics, Inc.$16K
- Otsuka America Pharmaceutical, Inc.$12K
- Alkermes, Inc.$7K
- plus $8K from 21 others
What the payments were for
- Consulting fees$31,4638%
- Speaking & faculty fees$316,57078%
- Travel & lodging$18,9575%
- Food & beverage$39,31410%
- Education$2190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 401 | $248,107 |
| Teva Pharmaceuticals USA, Inc. | 376 | $64,879 |
| AbbVie | 262 | $50,449 |
| Axsome Therapeutics, Inc. | 70 | $15,730 |
| Otsuka America Pharmaceutical, Inc. | 149 | $12,335 |
| Alkermes, Inc. | 126 | $7,080 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 70 | $1,729 |
| Johnson & Johnson | 82 | $1,406 |
| E.r. Squibb & Sons, L.L.C. | 29 | $685 |
| Vanda Pharmaceuticals Inc. | 36 | $662 |
| Supernus Pharmaceuticals, Inc. | 34 | $660 |
| Lundbeck LLC | 42 | $648 |
| Corium, LLC | 31 | $439 |
| Almatica Pharma LLC | 27 | $402 |
| Sunovion Pharmaceuticals Inc. | 27 | $327 |
| Bausch Health US, LLC | 30 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $281 |
| Janssen Scientific Affairs, LLC | 1 | $111 |
| Avanir Pharmaceuticals, Inc. | 5 | $73 |
| Indivior Inc. | 3 | $55 |
| Tris Pharma Inc | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Merck | 2 | $27 |
| Braeburn Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$242,531
- UZEDY$56,233
- VRAYLAR$46,726
- LYBALVI$15,410
- Auvelity$14,632
- REXULTI$10,113
- ARISTADA$2,418
- AUSTEDO$2,074
- CAPLYTA$726
- ARISTADA INITIO$667
- ABILIFY MAINTENA$500
- Austedo XR$440
- QELBREE$250
- COBENFY$244
- Fanapt$243
- VIVITROL$229
- ABILIFY ASIMTUFII$125
- Azstarys$114
- SPRAVATO$106
- INVEGA SUSTENNA$105
How this compares
$406,523 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 120 | $358,410 |
| IngrezzaValbenazine Tosylate | 35 | $273,079 |
| Austedo XrDeutetrabenazine | 30 | $175,049 |
| Invega TrinzaPaliperidone Palmitate | 15 | $103,265 |
| AristadaAripiprazole Lauroxil | 19 | $59,373 |
| LybalviOlanzapine/Samidorphan Malate | 39 | $58,222 |
| VraylarCariprazine Hcl | 32 | $44,233 |
| Abilify MaintenaAripiprazole | 13 | $35,321 |
| CaplytaLumateperone Tosylate | 19 | $32,511 |
| Aripiprazole | 113 | $6,714 |
| Clozapine | 73 | $6,128 |
| TrintellixVortioxetine Hydrobromide | 11 | $4,640 |
| Quetiapine Fumarate | 242 | $4,126 |
| Divalproex Sodium ErDivalproex Sodium | 60 | $2,440 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 67 | $2,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,406 | $461,675135 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $248,107 | $273,07935 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $64,879 | $175,04930 claims |
| Alkermes, Inc.Aristada, Lybalvi | $7,080 | $117,59558 claims |
| AbbVieVraylar | $50,449 | $44,23332 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $12,335 | $35,32113 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,729 | $32,51119 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $281 | $4,64011 claims |
| Almatica Pharma LLCSertraline Hcl | $402 | $677131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Marlton
- Aaron SpectorMarlton$100K
- Regina GarbarinoMarlton$12K
- Stella OkahMarlton$7K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.